<SEC-DOCUMENT>0001193125-15-174803.txt : 20150506
<SEC-HEADER>0001193125-15-174803.hdr.sgml : 20150506
<ACCEPTANCE-DATETIME>20150506170706
ACCESSION NUMBER:		0001193125-15-174803
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150506
DATE AS OF CHANGE:		20150506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORASURE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001116463
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				364370966
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16537
		FILM NUMBER:		15838095

	BUSINESS ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
		BUSINESS PHONE:		5036416115

	MAIL ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d921696d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;6, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Technologies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-16537</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-4370966</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>220 East First Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bethlehem, Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>18015-1360</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: 610-882-1820 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 &#150; Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2015, OraSure Technologies, Inc. (the &#147;Company&#148;) issued a press release announcing its consolidated financial results for the quarter
ended March&nbsp;31, 2015, and providing financial guidance for the second quarter of 2015. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item and attached Exhibit shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such
a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the
information contained in this Current Report or attached Exhibit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 &#150; Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2015, the Company held a webcast conference call with analysts and investors, during which Douglas A. Michels, the Company&#146;s President and
Chief Executive Officer, and Ronald H. Spair, the Company&#146;s Chief Financial Officer and Chief Operating Officer, discussed the Company&#146;s consolidated financial results for the quarter ended March&nbsp;31, 2015, provided financial guidance
for the second quarter of 2015 and described certain business developments. A copy of the prepared remarks of Messrs. Michels and Spair is attached as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item and attached Exhibit shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such
a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the
information contained in this Current Report or attached Exhibit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 &#150; Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May&nbsp;6, 2015, announcing consolidated financial results of OraSure Technologies, Inc. for the quarter ended March&nbsp;31, 2015, and providing financial guidance for the second quarter of 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Prepared Remarks of Douglas A. Michels and Ronald H. Spair for OraSure Technologies, Inc. First Quarter 2015 Analyst/ Investor Conference Call Held May&nbsp;6, 2015.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Signatures </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">O<SMALL>RA</SMALL>S<SMALL>URE</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May 6, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Jack E. Jerrett</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Jack E. Jerrett</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Senior Vice President, General Counsel and Secretary</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Index to Exhibits </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May&nbsp;6, 2015 announcing consolidated financial results of OraSure Technologies, Inc. for the quarter ended March&nbsp;31, 2015, and providing financial guidance for the second quarter of 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Prepared Remarks of Douglas A. Michels and Ronald H. Spair for OraSure Technologies, Inc. First Quarter 2015 Analyst/ Investor Conference Call Held May&nbsp;6, 2015.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d921696dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g921696ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Contact: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ronald H. Spair</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">610-882-1820</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Investorinfo@orasure.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>www.orasure.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Announces 2015 First Quarter Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETHLEHEM, PA</B> &#150; May&nbsp;6, 2015 &#150; (Globe Newswire) &#150; OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic
tests and specimen collection devices, today announced its consolidated financial results for the first quarter ended March&nbsp;31, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial
Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consolidated net revenues for the first quarter of 2015 were $27.1 million, a 15% increase from the comparable period of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net product revenues for the Company&#146;s OraQuick&reg; rapid HCV test were $2.2 million for the first quarter of 2015, representing a 39% increase over the first quarter of 2014. Total HCV-related revenues, including
exclusivity payments recognized under the HCV co-promotion agreement with AbbVie, were $5.5 million for the first quarter of 2015, $3.9 million higher than the same period last year. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net revenues generated by the Company&#146;s molecular collection systems subsidiary, DNA Genotek (&#147;DNAG&#148;), were $6.7 million during the first quarter of 2015, representing a 17% increase over the first
quarter of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consolidated net income for the first quarter of 2015 was $113,000, or $0.00 per share, which compares to a net loss of $5.6 million, or $0.10 per share, for the first quarter of 2014. This improvement was primarily the
result of the AbbVie exclusivity revenues of $3.3 million and lower sales and marketing expenses. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cash and short term investments totaled $89.5 million and working capital amounted to $105.6 million at March&nbsp;31, 2015. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased with our financial performance for the first quarter,&#148; said Douglas A. Michels,
President and CEO of OraSure Technologies, Inc. &#147;Increased HCV-related revenues and higher sales from our molecular collections systems business were the primary reasons for this performance and will set the stage for a successful year.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated net product revenues
for the first quarter of 2015 increased 1% from the comparable period of 2014, primarily as a result of higher sales of the Company&#146;s molecular collection systems, OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCV and
Intercept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> products. These increases were partially offset by lower sales of the Company&#146;s cryosurgical systems, OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
professional HIV and OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated net revenues for the first
quarter of 2015 also included $3.3 million of exclusivity payments recognized under the Company&#146;s HCV co-promotion agreement with AbbVie. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated gross margin for the three months ended March&nbsp;31, 2015 was 63% compared to 59% for the three months ended March&nbsp;31, 2014. Gross margin
for the current quarter improved largely as a result of the $3.3 million in AbbVie revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consolidated operating expenses decreased to $17.3 million
during the first quarter of 2015 compared to $19.5 million in the comparable period of 2014. This decrease was primarily due to lower promotional expenses associated with the Company&#146;s OraQuick&reg; In-Home HIV test, partially offset by higher
research and development costs and legal fees. Promotional expenses for the OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test were $432,000 and $4.6 million for the first quarters of 2015 and 2014, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash and short-term investment balance totaled $89.5 million at March&nbsp;31, 2015 compared to $97.9 million at December&nbsp;31,
2014. Working capital was $105.6 million at March&nbsp;31, 2015 compared to $104.8 million at December&nbsp;31, 2014. For the three months ended March&nbsp;31, 2015, the Company used $6.6 million to fund operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Second Quarter 2015 Outlook </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects
consolidated net revenues to range from $29.0 to $29.5 million and is projecting consolidated net income of approximately $0.00 to $0.01 per share for the second quarter of 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Financial Data </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except per-share data) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Unaudited </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Results of Operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of products sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings (loss) per share:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Net Revenues by Market and Product (Unaudited</B>) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollars</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Total Net<BR>Revenues</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:25.75pt; font-size:8pt; font-family:Times New Roman"><B>Market</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infectious disease testing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Substance abuse testing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cryosurgical systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Molecular collection systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance risk assessment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net product revenues</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:49.55pt; font-size:8pt; font-family:Times New Roman"><B>HIV Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic OTC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net product revenues</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:52.25pt; font-size:8pt; font-family:Times New Roman"><B>HCV Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net product revenues</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of exclusivity payments</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net HCV-related revenues</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:70.45pt; font-size:8pt; font-family:Times New Roman"><B>Intercept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Intercept&reg; revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:108.35pt; font-size:8pt; font-family:Times New Roman"><B>Cryosurgical Systems Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic professional</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International professional</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic over-the-counter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International over-the-counter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cryosurgical systems revenues</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Balance Sheets (Unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><U></U></B><U>Assets<B></B></U><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">189,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><U></U></B><U>Liabilities and Stockholders&#146; Equity<B></B></U><B></B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">189,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three&nbsp;months&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Additional Financial Data (Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company will host a conference call and audio webcast to discuss the Company&#146;s 2015 first quarter financial results, certain business developments and financial guidance for the second quarter of 2015, beginning today at 5:00 p.m. Eastern Time
(2:00&nbsp;p.m. Pacific Time). On the call will be Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Chief Financial Officer and Chief Operating Officer. The call will include prepared remarks by management and a
question and answer session. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to listen to the conference call, please either dial 844-831-3030 (Domestic) or 315-625-6887 (International) and
reference Conference ID #19423338 or go to OraSure Technologies&#146; web site, <U>www.orasure.com</U>, and click on the Investor Relations page. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to
the call. A replay of the call will be archived on OraSure Technologies&#146; web site shortly after the call has ended and will be available for seven days. A replay of the call can also be accessed until May&nbsp;13, 2015, by dialing 855-859-2056
(Domestic) or 404-537-3406 (International) and entering the Conference ID #19423338. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About OraSure Technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies
designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick&reg; platform, oral fluid sample collection, stabilization and
preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure&#146;s portfolio of products is sold globally to various clinical laboratories, hospitals, clinics,
community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians&#146; offices, commercial and industrial entities and consumers. The Company&#146;s products
enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied
in these statements include, but are not limited to: ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance
standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory
requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties
and reliance on strategic partners for the performance of critical activities under collaborative arrangements; our ability to achieve financial and performance objectives under the HCV co-promotion agreement with AbbVie; failure of distributors or
other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; impact of replacing distributors; inventory levels at distributors and other customers; ability of DNA Genotek to achieve its
financial and strategic objectives and continue to increase its revenues; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of
negative economic conditions, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and
market new products, including the OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance
or other factors, including changes in CDC or other testing guidelines, algorithms or other recommendations; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product
distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained
profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of OraSure&#146;s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of
litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of
products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to
attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to
obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in the Company&#146;s Securities and Exchange
Commission filings, including its registration statements, Annual Report on Form 10-K </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the year ended December&nbsp;31, 2014, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects,
readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d921696dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Technologies, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 First Quarter </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Analyst/Investor Conference Call </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May&nbsp;6, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Prepared Remarks of Douglas A. Michels and Ronald H. Spair </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Please see &#147;Important Information&#148; at the conclusion of the following prepared remarks.</U> </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Introduction &#150; Doug Michels </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks
Rena. Good afternoon everyone and welcome to our call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As indicated in our press release, 2015 is off to a good start. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our first quarter financial results exceeded our guidance on both the top and bottom lines. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our molecular collections systems business delivered another strong quarter, with revenues up 17% over the prior year period. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sales of our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> rapid HCV test increased 39% over the first quarter of 2014. This represents 24% sequential growth from Q4 of that year. Together with the
$3.3 million in exclusivity payments recognized under our HCV agreement with AbbVie, total HCV-related revenues were $5.5 million for the quarter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The revenue growth, along with prudent expense management, generated a slight profit for the first quarter. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later in the call, I will provide an update on our HCV business, developments at DNA Genotek, the progress we have made on our new rapid Ebola test and the
performance of our In-Home HIV test product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So with that, I would like to turn the call over to Ron for his financial review. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>First Quarter 2015 Financial Results &#150; Ron Spair </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks Doug, and good afternoon everyone. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Revenues
&#150; Ron Spair </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our first quarter 2015 consolidated net revenues increased 15% to $27.1 million, compared to $23.5 million reported in 2014.
Our consolidated product revenues of $23.8 million increased 1% largely as a result of higher sales of our molecular collection systems, OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCV and Intercept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other revenues were $3.3 million in the current quarter and represent the recognition of
exclusivity payments under the AbbVie agreement. We did not record similar revenues during the first quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our overall infectious disease
testing revenues increased 4% in the first quarter of 2015, compared to the first quarter of 2014. Total HCV-related revenues, including the recognition of AbbVie exclusivity payments, increased 252% to $5.5 million in the first quarter of 2015
compared to $1.6 million in the first quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCV product revenues increased 39% to $2.2 million in Q1 from $1.6 million in the prior year.
Sales of our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCV professional product in the domestic market increased 81% in the first quarter of 2015 to $1.2 million from $663,000 in the prior year. This increase is largely due
to the addition of new HCV customers and higher sales to current customers who have expanded their HCV testing programs. International sales of our HCV test in the first quarter of 2015 increased 8% to $972,000 from $896,000 in the same period last
year, primarily due to higher sales into certain Asian markets as a result of regional expansion, partially offset by lower sales to Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Domestic
sales of our professional HIV product decreased 9% to $6.0 million in the first quarter of 2015, compared to $6.6 million in the first quarter of 2014. This decrease was the result of customers moving some of their testing to 4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> generation automated HIV </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immunoassays, price competition, and the timing of orders. We expect continued pressure on our professional HIV business for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International sales of our professional HIV product increased 70% to $948,000 in Q1 compared to $558,000 in the same period of last year. This change was
primarily due to higher sales in Asia and Africa, partially offset by a decline in Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the current quarter, net sales of our OraQuick<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test decreased 20% to $1.6 million compared to $2.0 million in the first quarter of 2014. The decline can be attributed to our decision in the second half of 2014 to focus our
marketing and promotional efforts at the retail outlet level and away from broad-based consumer advertising. As a result of the savings in advertising and promotional costs, this product line achieved profitability for the first quarter of 2015.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our molecular collection systems revenues, primarily representing sales of the Oragene<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> product
line, increased 17% to $6.7 million in the first quarter of 2015 compared to $5.8 million in the first quarter of 2014. Commercial sales increased 32% as a result of the timing of orders placed from certain existing U.S. customers as well as
incremental revenues from new customers. This increase was partially offset by a 7% decline in sales to academic customers due to variability in ordering patterns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Substance abuse testing revenues increased 15% to $2.1 million in the first quarter of 2015 compared to $1.8 million in 2014. This increase is largely due to
higher sales of our Intercept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device as a result of the recovery of customers previously lost to competition and improved domestic employment conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First quarter 2015 cryosurgical revenues decreased 36% to $2.5 million from $4.0 million in the first quarter of 2014. Domestic sales of our professional
product decreased 57% to $661,000 in Q1 from $1.5 million last year as a result of distributor consolidation and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competition from new private label brands. Sales of our OTC products in the international markets decreased 30% to $1.5 million in the first quarter of 2015 compared to $2.1 million in the first
quarter of 2014 due to lower sales to both our European distributor, Reckitt Benckiser, and to our Latin American distributor, Genomma. The decline in sales to Europe was due to customer ordering patterns. The decline in sales to Latin America was
due to ordering patterns and challenges faced by Genomma, including declining economic conditions in Argentina. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Gross Margin &#150; Ron Spair
</U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross margin for the first quarter of 2015 was 63% compared to 59% reported for the first quarter of 2014. The current quarter margin
benefited primarily from the $3.3 million of revenues recognized from our AbbVie relationship. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Operating Expenses &#150; Ron Spair
</U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated operating expenses for the first quarter of 2015 decreased to $17.3 million compared to $19.5 million in the first quarter of
2014. This decrease was primarily due to lower promotional expenses associated with our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test, partially offset by higher R&amp;D costs associated with the development of
our fully-automated high-throughput drugs-of-abuse assays and higher legal fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Net Income &#150; Ron Spair </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From a bottom line perspective, we reported net income of $113,000, or $0.00 per share, for the first quarter of 2015, compared to a net loss of $5.6 million,
or $0.10 per share, for the same period of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Cash Flow from Operations and Liquidity &#150; Ron Spair </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Turning briefly to our balance sheet and cash flow, we continue to maintain a solid cash and liquidity position. Our cash and short-term investment balance at
March&nbsp;31, 2015 was $89.5 million compared to $97.9 million at December&nbsp;31, 2014. Cash used by operating activities in the first quarter of 2015 was $6.6 million compared to $7.7 million used in the first quarter of 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Second Quarter 2015 Consolidated Financial Guidance &#150; Ron Spair </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Turning to guidance for the second quarter of 2015, we are projecting consolidated net revenues of approximately $29.0 to $29.5 million and consolidated net
income per share of approximately breakeven to a penny per share for the quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And, with that, I will now turn the call back over to Doug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Business Update &#150; Doug Michels </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks, Ron. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>OraQuick</U></I></B><U><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP><B><I> HCV &#150; Doug Michels </I></B></U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our HCV business continued to grow in Q1, with 24%
sequential growth and 39% growth over the first quarter of 2014. We shipped product to over 460 customers during the first quarter and 86% of our revenues came from repeat customers. We also added 64 accounts during the quarter that had not
previously ordered OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCV tests from us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As you know, a major focus of our HCV business
has been, and will continue to be, our co-promotion agreement with AbbVie. We have been pursuing several major initiatives under this collaboration. As we have executed against each initiative, we have gained important knowledge and adjusted our
strategy in response to evolving market conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market for HCV drug therapies has been developing very rapidly during the last year or so. As you
might be aware, decisions today regarding which pharmaceutical products will be most accessible to patients are often influenced by insurance companies and other payors. In many cases, in an effort to reduce costs, payors negotiate discounted prices
for drug therapies in exchange for giving those therapies a preferred or exclusive status on their formularies. Not surprisingly, the competition among HCV drug manufacturers to secure this favorable formulary status has been intense. This
competition and the outcome of these negotiations influence where manufacturers focus their resources in order to provide the highest potential yield of new scripts for patients. These developments have affected our co-promotion efforts with AbbVie.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One example of this is in our largest initiative, directed to primary care and specialty physicians. Our approach
under this initiative has been to combine detailing by the AbbVie sales force with our promotional activities through several large med-surg distributors and manufacturer representative organizations, or &#147;MROs&#148;. As a result of increased
focus on its new HCV therapy, AbbVie reduced the physician detailing activities by its sales force for our HCV test during the first quarter. While not unexpected, this lower level of detailing will likely last through the second quarter as the
competition for scripts settles out in the market. We anticipate AbbVie&#146;s detailing of our product will resume to a more normal level sometime in Q3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the meantime, we have adjusted our approach by increasing the focus and efforts of our distributors and MROs to more effectively generate sales leads and
customer interest within the physician market. We have also continued working to address work flow matters, reimbursement questions and other issues raised in the field that might delay or prevent a purchase decision by physician offices. We will
continue working with these customers to accelerate the decision-making process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A second initiative is directed at national and regional retail
pharmacies and retail clinics. As indicated during our last call, we are planning to initiate several pilot programs with the goal of developing sustainable models for rapid HCV testing in retail outlets. One national pilot and a regional pilot will
begin later this month and we expect a second national pilot to start shortly thereafter. The goal of these pilots is to develop a retail program that can be deployed on a national basis. Any revenue contribution from this initiative this year will
be modest, but our expectation is that these pilots will be successful and that the retail market becomes a substantial contributor in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A third initiative covers employer groups and was initially focused on the commercial long-haul trucking
industry. This initiative has not developed the way we expected, in part, because of the competitive market conditions I just mentioned. As a result, we have terminated some of our industry-specific collaborations under this initiative, although we
still believe truck drivers represent a potentially attractive target market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In an effort to broaden our approach to employers beyond trucking, we are
working with AbbVie to identify other work groups that may offer opportunities to promote both the use of our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCV test along with AbbVie&#146;s Patient Support Program. We believe a
number of attractive employer groups will be identified through this screening process. Together with AbbVie, we are finalizing this review and we expect to focus our resources on new employer groups that are identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AbbVie and OraSure have also been looking at ways to expand our collaboration beyond the current agreement. One potential growth area is the public health
market. Many public health customers are already using our rapid tests for both HIV and/or HCV, and this provides a great opportunity to promote either the initial or expanded use of our HCV test. Given the limited resources in public health
jurisdictions, a program such as AbbVie&#146;s Patient Support Program is something that our public health customers find attractive. Based on initial discussions with over 100 public health customers, interest is quite high for combining the use of
our rapid HCV test with AbbVie&#146;s Patient Support Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, both OraSure and AbbVie remain committed to our co-promotion agreement. We
continue to believe it represents significant opportunities for both companies and we intend to devote the focus and resources needed to maximize the success of this important collaboration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Molecular Collection Systems &#150; Doug Michels </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Another area I will touch on is our molecular collection systems business. As Ron explained, DNA Genotek continued its run of strong quarterly performances
with 17% revenue growth over the prior year quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DNA Genotek&#146;s revenues were split 60% commercial customers and 40% academic, which is consistent with past
performance. During the first quarter, all of the growth occurred in DNA Genotek&#146;s commercial business while academic sales declined compared to the prior year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One particular strength on the commercial side is in the area of pharmacogenomics, which uses genetic testing to study a person&#146;s expected response to a
particular drug treatment. Our pharmacogenomics customers accounted for double digit growth during the first quarter compared to 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Another growing
part of DNA Genotek&#146;s business is in the area of reproduction genetics and breast cancer screening. We now believe DNA Genotek is the primary DNA collection device supplier for a majority of the leading companies in both areas. As you may know,
the breast cancer screening market in particular is growing rapidly and we expect this part of the market to continue to deliver strong results in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the first quarter, DNA Genotek was successful with 23andMe, its largest commercial customer, in obtaining FDA 510(k) clearance for the Oragene<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> &#149; DX saliva collection product. 23andMe uses this device to collect samples from its customers. Our 510(k) clinical study confirmed that the Oragene<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#149; DX device is reliable and easy to use for consumers at home, while also providing high quality DNA samples for processing in a laboratory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As you may recall, DNA Genotek is also pursuing 510(k) clearance of its ORACollect<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device. I am
happy to report that this clinical work is progressing well. We expect to submit our 510(k) application to the FDA during the third quarter of this year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, as you know DNA Genotek is based in Canada. The strengthening U.S. dollar relative to the Canadian dollar delivered both expense savings and foreign
currency exchange gains during the first quarter, all of which positively contributed to our consolidated bottom line results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Rapid Ebola Test &#150; Doug Michels </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed on prior calls, our newest product in development is a rapid Ebola antigen test on our
OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform. During the past several months we have been working diligently to fully develop, fund and deploy this new product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the first quarter, we locked the design of a prototype device that appears to deliver analytical performance similar to PCR tests when evaluated on
stored samples from infected patients. During the first quarter, we also recognized revenues from the initial sales of this product to the CDC for investigational use in Africa. The data generated from this field testing, along with other clinical
and non-clinical studies we will perform, is expected to be used in an application to obtain Emergency Use Authorization from the FDA during the next several months. We also intend to use this data for similar approvals internationally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also continued discussions with governmental agencies in an effort to obtain external funding for our development efforts. Good progress has been made
and we are optimistic that we will be able to share some positive news on this funding effort in the very near future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On a parallel path, we have
engaged with many governmental and other entities to identify and secure one or more purchase commitments for the product once approved for use. As explained previously, our ability to successfully obtain development funding along with substantial
and sustainable product purchase commitments is critical to the future of this product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>HIV OTC &#150; Doug Michels</U></I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A final area I will briefly touch upon is our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test business. Because we have
implemented a more cost effective promotional strategy, I am happy to report that this product line achieved profitability during the first quarter of 2015 and we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expect this product to be profitable for the year. We also intend to continue to look for ways to grow this business in a profitable manner. Along these lines, we are pleased to announce that we
recently received CE mark approval for our OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test. We are continuing to assess various go-to-market strategies in certain European markets, but will only launch in these
additional markets if we can demonstrate a pathway to profitable expansion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Conclusion </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So, as you heard today there is no shortage of exciting growth opportunities before the Company. We believe we have the right strategy and resources in place
to achieve our goals and objectives for the year. And we look forward to updating you on our progress during our next call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With that, I will now open
the floor to your questions. Operator, please proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>[Q&amp;A session] </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Final Conclusion
&#150; Doug Michels </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for participating on today&#146;s call and for your continued interest in OraSure. Have a good afternoon and
evening. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Important Information </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document
contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual
performance or results to be materially different from those expressed or implied in these statements include, but are not limited to ability to market and sell products, whether through our internal, direct sales force or third parties; ability to
manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or
applications for existing products; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators;
changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; our ability to achieve financial
and performance objectives under the HCV co-promotion agreement with AbbVie; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; impact of replacing
distributors; inventory levels at distributors and other customers; ability of DNA Genotek to achieve its financial and strategic objectives and continue to increase its revenues; ability to identify, complete, integrate and realize the full
benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers;
competition from new or better technology or lower cost products; ability to develop, commercialize and market new products, including the OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV test; market acceptance of oral
fluid testing or other products; changes in market acceptance of products based on product performance or other factors, including changes in CDC or other testing guidelines, algorithms or other recommendations; ability to fund research and
development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third
parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of OraSure&#146;s stock price;
uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter
into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms;
adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the
impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in the Company&#146;s Securities and Exchange Commission filings, including its registration
statements, Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should
keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this call, and we undertake no duty to update these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g921696ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g921696ex99_1logo.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,J:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C4M8S`R,2`W.2XQ-30Y,3$L(#(P,3,O,3`O,CDM
M,3$Z-#<Z,38@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;7`Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#0R`H5VEN9&]W<RDB('AM<$U-
M.DEN<W1A;F-E240](GAM<"YI:60Z03E!,CDY,#1&,S=!,3%%-#@Q1D)%041%
M-3!$-S(V0D8B('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z03E!,CDY,#5&
M,S=!,3%%-#@Q1D)%041%-3!$-S(V0D8B/B`\>&UP34TZ1&5R:79E9$9R;VT@
M<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#I!.4$R.3DP,D8S-T$Q,44T.#%&
M0D5!1$4U,$0W,C9"1B(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#I!.4$R
M.3DP,T8S-T$Q,44T.#%&0D5!1$4U,$0W,C9"1B(O/B`\+W)D9CI$97-C<FEP
M=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB
M<B(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!
M`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`&0!5P,!$0`"$0$#$0'_Q`#5``$`
M`00#`0$!````````````"`,&!PD$!0H!`@L!`0`!!0$!`0`````````````&
M`0($!0<#"`D0```&`0,"`P(&#0<+!0````$"`P0%!@<`$0@2$R$4"3$505$B
M,A8789'1(S-3)%1FII<8"O!Q0E)BDUB!L7*"DD,TMCAX&;(EM7<Y$0`!`@0$
M`@4&"@4'"P4````!`@,`$00%(3$2!D%187$B$Q2!,E(C%0>1H;'!T4*B8Y,6
M8G)451>"LL(S0R1U\.&24[,T9'0U-@AS1"4W"?_:``P#`0`"$0,1`#\`A$XY
MO<^2KK%+R\Y!E*550I0#(,OL``80``\?8`:^\!MC:,A_\;1?A(^B/EQ=RW(%
M$"NJI3_UBOIBC^^_SZ_Q>\@_V@R_W=/RQM']VT/X2/HBWVEN3]NJOQ%?3#]]
M_GU_B]Y!_M!E_NZ?EC:/[MH?PD?1#VEN3]NJOQ%?3#]]_GU_B]Y!_M!E_NZ?
MEC:/[MH?PD?1#VEN3]NJOQ%?3'+8<T/4'E7S6-C>6?(E[(/E009LV]_ESN'2
MXE,<J*"8#NHJ<I!Z2AXB/@'CJU>V]GMI*UVZA"!F2TC#XHN3<-S+4$IK:HJ.
M0[Q7TQPPYP\^3`!@Y?<@Q`0`0$,@R^P@/B`^W5_Y8VC^[:'\)'T1;[3W)^W5
M7XBOIBX)3EWZAT/"U*?><N>0)8ZZL)F1A%2Y!F-U4(*==UV1`_CL!TI%F8/#
M^B(:\6]O[.<<<93;:+6T0%>J1]9(4.'(QZ*KMS(0APUU5I6"1ZQ7`R/'G'3M
M>:WJ!OG+=DSY;<B'3MVL1NU;(7Z847<+JCTIHHIEW,=0X^P`UZ*VUM!*2I5M
MH0D#$]TCZ(L%QW*HA(KJLD_>*^F*'[\'/K_%[R#_`&@R_P!W5?RQM']VT/X2
M/HBGM+<G[=5?B*^F'[[_`#Z_Q>\@_P!H,O\`=T_+&T?W;0_A(^B'M+<G[=5?
MB*^F'[[_`#Z_Q>\@_P!H,O\`=T_+&T?W;0_A(^B'M+<G[=5?B*^F'[[_`#Z_
MQ>\@_P!H,O\`=T_+&T?W;0_A(^B'M+<G[=5?B*^F-ROH1<F.565>>):GE_D!
MEG)%-'"V0I,U:N5L?S,,,JS?5DK&0%FY^]^;:%74!,_M*!Q^/7-/>U9-OT.S
ME5%NHJ9BI\4T-:&TI5(ZIB8$Y'C$TV!6WA_<(;KJE]UCN%G2M94)S3(R)S&,
M>T;7RU'<8:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0A
MI"&D(:0AI"&D(:0AI"&D(:0AI"/YECC'H"X7'L!XK*?`/]<?L:^\Q4X1\[JH
MIJ)E%'ZO`_$!]H?N:KXJ*>!Z(?5X'X@/M#]S3Q4/`]$9"I''U]D&-NB5;14>
MV^HUYS=T*RFGW'-DIT$43W12$(7[ZZG*FP.23.V*!C.(U)T<@=:&Q\*KNS=$
MMHOX4SBPC5P2M7F:N25GL@\%%(.<>[-K[]*P@3=0G5+FD>=+I2,9<1/E%L56
M"<4VSU:[1R)#.ZA9*];F0[`=-16NRS*;3((?-42<`SZ#![#$,(>P=9%0M-2P
MY2K\UU"D'^4"GYX\VJ8L.I?2.TA04/(9Q);F]Q8882Y*7ZOUMD),=W(T?EK%
M#@$A307QQDU`UG@FC<?E%,2`<.G$8.PCMY,-:':=^5=K$R\^?[ZU-EX<G6NP
MHG]:05_*C87BSHI+@M#0_NZ^VC]1>('DQ'DB]\XX&(QX+<![Z1J`*2<MRAK#
MT_;V$P?6.PL$3UGVW,!B"\Z-_@*/LUBVFZZ]VWBB)\U-(H?A%*OFCVK;:!9J
M%V6,W@?],$?/%F\3<"IOUL]YFDF130''3C[D*])J*IF%NID"UQBV/,9,>OH,
M3S1)RPK2"91VW]W>W<0UD[CNF@4=K0?75M:VWT]V@]XZ>K2D)_E1YVNV))>K
M%CL4["E?RU#0CXS/R1$1+'7:123\N)S$(DD`$(=110^Q4RD33(4QU%5#[`4I
M0$QC"```B.I*:J9)C4^"`&49#R3Q]D,860E)L"8$N$7$1+JZ1(%+M5+!,,TY
M;Z(.5"B;N3<#%NVQ)(OL;OSJ-_G(FUA4-V;KV/%,_P"[*40@^FD&6L?HJ(.G
MFF2N(C(J+6:=SN5CUH`U#T2<=/6!*?(S'"+!^KP/Q`?:'[FLSQ4>'@>B'U>!
M^(#[0_<T\5#P/1&Y;T(JE[FYW^=[71MA7(*6X!^,?UG[']G7,_>V_P!YLU2?
M^*:_I1*]ETW=7P+E_8K^:/:'KY7CKT-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#
M2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA'@87QR/>5_)S?
MA5/_`%#]C7V>*O`8C*.-^''(Q3^KD?S<W\O\FGB^F'AQR,9?QKQR99;*>H5E
MTWB<ME[R]6@)IXBS@<I(D(992M0TLZ,DW@,B($*863=R<&4RF':(=%R4H+ZN
MX7M=L_O50-5LP"U)$U-<-:@/.:](CM(S(*<LFGH!4^J;PJ>`)D%]`/!7('!6
M6!SM^G0MZP?D^OW*&CY"MY#Q?:VDHC&R[-9B]92T0XV>P<U'.DTU2M9-H95F
M[04+TK-ESE$!*;Q]ZI='=[>NE=4ERBJ&B)I((*5#!22.(,E)(R($6-(=I*A+
MJ`4OMJG(\QP(Z<CT1*/F%Q#J\4RJ7);",0<G'W/35*::Q#<O6GBN]295E)^@
M.P(0I6L2$HDY+'[@4$E$E6OL32$\=VON2H<6[M^[*'MNB.DG_7-CS7!S,I:N
M8(5Q,MA=+6TD)KZ0?W)X3EZ"CFGJG.7+$<HE-R@PH&>?3NXH\AF#47EPPI4(
M_&]S7(3K=+TI!\%1.+M3Q,8D!8HAJN7?\&F\6-[!'4=V_=?8^^;E8UF5+5N%
MUOEWA&O#]9)(ZTB-C<*3QMDIJT";C2=*OU<OB('PQ^,X892?^D/Q5?$9_E=)
MO?OQ0>GY23.Z3M]C79Q\/`BJLDV$?9[`TM%S*/>;<FR>RZSI\K:6R/D,4JZ3
M5MFF,L4+GY%%0^<1:33"888]*"WRR[3R]GY596I(N=P`CDU(@IA1W7&A@$H*
M=A=E6';W;<2B1\`_#K*5=/:OO(:929T]NIG.KO%)DH]8*TI_DQYBD\)MQ:B.
MW4.)_P!$'#X@3Y8QSP[XR0M&I=VYOY;@D'M(PRV<+X?J\HF0S;(N84U2L*T[
M4;*AL\@*W8W"`$``$BS\!-XD:J`.=NB_.U=6SM&V+(K*LCOEC-IC-8GP4I(/
M4GI4(\;7;D,M+NU2F;37F`_67P\@,NL]40$D*38[E8W\M*$DK)<+C8'LG(JI
M).)&6L%GL<BL^>&002(LZ>O9&3=G$I"`8YA-L`:FB*EBE82VWI;I6D`#(!*$
MB0QX``1I5,K=<*E:E.J5,\223\YB[\@<>5L:+MJU95DSY$*5-S9JS'+(.FM#
M362!1M7K#(HF51<W=0BA5'C)N84XHHE26.9P)TT<6AO(N"344X_N.2%D2+G-
M21P;X)4?/S`TR)]'J'N#W;G]?Q`/F]!/I<QPXXY8Y^KD?S<W\O\`)K/\7TQX
M^''(QM*]'RGC"\OU'_9$@%Q1<D>H0]G=?P'\VV_3KGWO.J.\VJI$_P#W#?\`
M2C?[99T74*^[5\T>J'7SC'18:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI
M"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"/)LKB$PJJ"#?VG,/B3X
MQ$?9\&OID7+#..=>%Z(N"MX?JKAP9C;BR\6S<B4$;'!MTY)Q#*>`=U]7W"B!
M)N,$?%0B*R#H@?*3$X_>Q\*BY5*4ZZ70I8^JHR"NI0GI/*8(YRSB]%*V3)T$
M#F,9>3B/CB]K/P^O57C6UNB4&MQI:AB/(S(%!<.)*+2%!0JJ+AT5(B$W6W[1
M4I1,5RBD=NJ'SMPWUATVYZ.I<-*Z2U69%IT`'R9I6#T$@CA'JY;'6TAQ,E-9
MA2<1](,3`J5*H'-"LM:7ET[>M\BJW%`TJF6F;=`KG($1'I;-VMJ;%%%&=D6*
M1=G!#B"YB!WT#E'NDU%ZJJKMI5!J[9-RPN*FMDG!M1S*#]4'@<I]E0R,;-ME
MBZ-AJIDFN2,%^D.GF>?PB,G<9<3RU!;Y%X:<@8!-]2;^WDIREKBH9>#E'!2)
MC/)UJ3,F44G)P11DVY=DW#1T@H82`80$==N&Y-5I8W98URJV"$N#)0'U=8Y9
MH/!0(X1[T%,ID+M=:)M+F4\CSD?C'$&)%<<^/BE"Q!E;C5>4E)JI_2&T-(24
M61`$9ZB7J.27;.B%'=-*1:/3NB+D+X).DQ,7Y(E$=#?KX*VZ4VX*,Z*GNT%0
MXI<;.(ZB)2Y@QG45%W-,Y0NXMZC(\TJ'RY^6.-8N,4C-<*HOC:L**LQ&0E<A
M$G8')V@6B;6S>*28'WZ=Q8$46V]NX[>W5S&X6V=VJOXGW*EJ5+]9!$OAD(HY
M0%=J%#]8`#X#G'2<H..09B;\><!5XBT/0JL]<3%F?-DP*2%J-6@VM>CT&Y@*
M"0R\D5^=NU`0\#B940Z2&U[;=OWLHUU[?DNM<`2@'ZRUJ*C/]$2F?@XQ97T/
MB0S1HP929GH2!(>7'#X8P7S+I$ID)]BOB-A&ME^C](8,)N3@XL`;14:<C8T=
M6DI=R;9!FRB6"BSM9=81,HJY3-\M4?'<[4JFZ)NIW1>'/7O**0I6*CC->D<2
MHR2`,@#D(Q+HRIXMVVD3ZM`!(&0X"?0!,^6,2S^+:;PTKYH2DJL+?R>L<:*<
MED$S8JK'$<-((B1?Z&LW!3E8S[](XD;N5"^;$GWX_;3Z$C[-BX5>['^^JP6M
MNMJP;GB^H'^T(S2.(\W@)F9&,NF:M:-#4E7!0Q5P0/T1S/`Y\>B(/P/'RU7)
MZY2@(*3L+P#+/))VF4ZR3<5#F6=2,W,.SD9LB'4.915=TL0!$1,(B(ZF#UZI
MJ5`+ZTH1D!SY!*1B>0"1&J11..GL#4>/TD_28X$IA(L:Z%F1W&RBJ0"5RO$G
M.ZCTUP'8R#=^9-))_P!L0V,HB!D1'YICAXZO;NO>)U$*2#EJP/E'#J./,"+5
M4FDRP/5E_GB</ISX_-7.0CF3%(";4"P-^KIV_#/HCPW_`-343WU6=_8"W.?K
MD?THVEE8[NN"OT#\T;V]<5B80TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#
M2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$:J_J%.=7860$(8VPG,
MD)@*`C\X0((F$/Y@'73O;20G/&(]X,G&4=J3C1*KI]UC'M9$GP^0<(+*E_TV
MQSHNB"'V2:\CN%E)DM12>D'Y<OCB[P"CD`8O"A4O(.)Y0[VO(O&3=T<HRL*\
M06]SRY"?)$';8P@4C@""(%73Z52AX;B7P'$KJNWW1H)?(*ADH><GJ/+H.$>K
M+;].J:,!Q'`QFQ?#V+LFG2L+&%7Q[>FJR;[SU?%./>-9%`X'2?%12*5A(%(L
M'4"I2)JC_2$-]ATPNMRMLV%K%11$2DK$$'A/,=4R(RO#4[YUI&AX8X<_GC.S
M&"<OXR,:W1*,FI2%=MW;2700%'N/6?\`PTPW1-NK%R!BB(*%3.)?$P`(D,)=
M:1;R4.*51E2&U@@I)X'-)](<I_*)QEA!4D!V14#G\_08NW6+'K#2$?-@WWV#
M?;;?;QV#?8-_B#?2$8Z>5Q2LM)Y>A0K,UMMCY9Y(3D@8FQGJI03+)3#LX&7<
MMXU`"D;-2`)0`H$*4I>H=;!%0*E:$URSX5I,@D<N21D"3F3U\H\"WW8460.\
M4<2?E/5RB.?[M^/X!9U9<DO9'(%CD%U9!Q&HB=!*3D%CBHJHZ$JA7CDASB&Y
MU%4D@*&W1L`%UOSN"N?`I[<E+%.D2!SD!RX#R`GIC"-$RGMOS6X>'.+&NE;L
MUM9%K[6+:56DH&`S6FUYNFPB#"3I`B\J#<$32[O8H")E0Z`-X@4!\=9]&_2T
MJ^_4HNUAS<5BKJ3Z(ZL8\G4..#0`$M>B,O+SC&1<"+F\"QPF^P5+J_S".P:V
M)O;8S5&/X,\HSWQTQ8>HWE],':]G:ONF@&Z``=UW;,=M]Q]H)ZTM^N::F@[@
M&9*P?@G&514Y;?URPD8F[J%1MX:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0
MAI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI".#[LC_P`S;_W9=7]X
MYS,4TB/H1K`H@8K1`I@]ABD`#!_,8-A#3O'.9AI$<SI#;I$-P]FP_*^WOOOJ
MR*QQQ9M1.57RZ(*$'<JA4RE4*/Q@<H`8/MZNUJE*9E%)".3JV*QP9*28Q#)>
M1D7!&K1L4#*K*".P=1@*0A2AN8ZBAS`4I0`1,80`-:/<FY+)M&RO[AW%4(IK
M13)FMQ720E*0!,J6M1"4(2"I2B$@$F,FDI*BNJ$TM*DK?6<`/A/4`,23@!'6
M1MB2DBE5*Q?MFZ@`9)9TFFF)R#\TXI@H8Y"F#8?C^QJ,[>]X=)N%M-4W0UU-
M0.`%"WD)22DY**`HJ2")''&1Q`C,J[4NC)0IUI;HS"23(\IRD8N`!`0`0\0'
MQ`?C#704J2I(4D@I(P,:HB6!SC[JL(X9V#)0YE%&R)SF'<QSD`QA'[(CN.KP
MXL"0)E%)"/I6#$OS6;8/9_N4Q'P]GB)1'5-:SQ,)"*AFS<P=(HDZ?ZH%`I?M
M%V`=-2N<)"/B+1LW,)T$$DC&#I,8A0*(AOOL(A\&^A6I0DHDB``&4<C5L5CQ
M<\I)CE'S7Y>^J5,L.6^6L&U/TW*?)6?#]#QQ+2\-"2CVJL'JXA)!#3<."+V9
M<5YRLY?J%=.>XNB0@`BCVS?4NWV[!M;;>WF56ZFJJB^.!+SCJ4J4-9&(U)5,
M)"@`G`2!.9G'!;NN\;@OEY6*U^G9M2"6D-D@'3/.1&)TDE6)F1P$HWM^F]SO
MAL@>G[Q)S#RLRU3JUD;+"#O'[:>MTO%5Q?(]T@+)(UAGY%%8S5!]9)ILR047
M30*'<<*&,!0ZMM<CWQL]ZEWE<[=MRE=<H*:3I2A)4&D*0%F><D))($\@)1T7
M:NXVJC;5#6WE]M%6_-`*R$EQ:5%(EE-1D)RS,3>F.7O%^OXJG,XS6>,8QN(*
MY:)BDRV175JC251&W0$NX@9>N-97NBA)R[*8:*MQ0:BL<RB1^D#`41")M[8W
M"]<4VAJCJ%7-;:7`T$'7H4`I*B."2"#,RS$XD#E\M#5&;BY4LBA2LH*RH:=0
M)!2#Q(((D)Y&(6>H3SD9UKTQ,^<K^'>2JQ>G+2LL8BEY'I4@PLD=79"Q6F#J
M4C-E[??2;S-;:S1UDTG!"G0<]HRA.GVRG9>TEO;^H]N[GIW&05E2VG`4E82A
M2PGI2LIE,8$3`,:#<^XDM;1J;S8GD.$)"4K00H)*E!)/0I(,Y'(RG&FK@[BS
MG]QJY0<`,HU'-/(/EM@CF?C.)N_)IW+%M=QQKC=Q<6BJQ7$E-O)2;CF#JMN9
M-NX0?B+-P8Z#E,Z8HG`I>H;LK]H7W;]ZM]52T5NNUJJ%-TH&AMUW0?JI`2HA
M0!!2-0Q209B(+MZDW':KQ:ZQBHJJVW5[(6^3J6VWJ'$DD`I)!"L#,$9&/3.Y
MY@<6F=?R1:G>?\4-ZWAZ?:57*<VM<X4D;C^R/WZ\6R@[6Z,Z!*&DW4BV4031
M6$IS*$$H!N`ZX0G:VXUO4].BAJ2_5-E;*0VJ;J``2I`EVD@$$D<#'6%7ZRI;
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M5W^RT##536U3+3+P!;*E`:P0""GB1(@SRQB0=9L]<NE>AK;4)Z'M%7L4<VEH
M&Q5^1:2\+,Q;U,JS20C)-@JNS?,W"1@,11,YBF#V#K25%._2/KIJI"FZAM12
MI*@4J21F"#B".1C:,O-5#27V%)6RL`I4D@@@Y$$8$1JK]8'!N9,A\=)S+^(N
M5>5>-KKCC1,G9+E8C&:\@S#*01M;+(,8"?D&%AA5&#9F>*/VE03<F(9<P@7P
M\>B^[*\VR@O*;9<;=3UPKWF6DJ="3W,U$%20I"ISU"8FG+.(=O>VUU9;#6T5
M:_2&D;<<(;)'>23,)40I,I2P..>40P]"/&&?[7B&H\\LU<V<RY1K&1J%?J^X
MPIDF;DI:F4YQ"78S,MR"QS-F=$5>-&%95ZCG9H`DFZ/\OI*.\G][MRM#%P<V
M?;+53,5++S:N_:2E*UA3<]&A*`9$K'UC,@81H/=U17)VB;W)7W"H>9>:6.Z<
M4HI3)<M6I2CB`D\!GG&ZG#/,GBKR(M-EI.#<_P"+,I6ZGE55L5=IMMC)B58-
MD'/DUGY&B"W<?1B3H2IF=-^\W*8Y0$_RR[\LNNUMQV2G15W>BJ*>F<,DJ6@@
M$D3`GP,N!D>B)]07ZS71Y5/;JIEY]&:4*!(&4Y<1/B)B*5LYH<3:)E^+P#<N
M0^)*UF:94:(,,=3%TAV5D.ZD"%4CF+EJJY*2/D9(BA!;-W!TEW`*$[9#=9=U
M-M7<E9;%7FEH:ERUI!)<2@E,AF1S`XD3`D9G`Q1Z_P!EIJX6U^J817JD`@K`
M5,Y"4\">`.)X1I_O?)RP8L]=^S5O(^=9BC\:JKPO4O\`9:U:+TYA\4P\DV9I
ME/97<.^?)0:4H*JA"D4*05E53E*4#',`#TVBL35Q]SZ'*&D0]?7;J&T*0V%/
M*$_-"@-4N8G(#/"(/579RC]XZFZJI4W:46\K4E2R&@?2()TSZ<XW++\L^,K;
M'./LNNL[8O:XPRO),(;'%[=6Z);5FY2\F9<C&*@I19P1N\DEE&JI!0`05(=(
MY3%*8I@#EZ=L[@77OVM%'4&X4R2IUL()6A(E-2@,AB,<L01G$[5>[0FE:KE5
M+(HWB`VLJ`2LG()/$X'#/".[Q7R/P)G&6OL'A[+^/LER^+YGZ/Y!84RSQ<\O
M4Y<>\`-)<&#A8J'4=LJ4%`$R1CI'*!A,0P!XW&Q7FT-,O7.E?8:J$ZFRM!2%
MC#%,^L89XCG'I1W6V7%QUJA?:><95I6$*!*3TRZCT8'E%G8SYH<3LS9)G\/X
MIY#8FR!DZL^>&8I57N41*SB)8P_1)':-VZYBRR<<;\.9H9<J(`(G$``1UE7#
M:NY+50HN=QH:EF@7*2UH(3CE/T9\-4IQX4E_LM?5*H:*J8=JTSFA*P3AG+G+
MC*<HU<^F=F;)=QY]^L#6LBY/MUCHN*L[QC"CP=MM#Y]6,>P!'=Q\XUKS.0<C
M'UZ+*V8)BH"0)I@1(!'P#?70=^VVBI]F;9>HJ=I%744I*U(0`MQ6EJ6H@369
MDRG,S,1#:==5O;FOC-2\XNF9?3H2I1*4":YZ03)(PX2RC:5AGF7Q3Y$6FR4C
M!O(+%64[=4B*JS]=IEOBIF59M4%R-EWZ31NN*DA&(.%"D.Z;=YN0YR@)P$Q=
M^>W3:VX[)3(J[M15%/2N&25+04@DB8$^!EP,CGAA$PH+]9;H\JGMU4R\^C-*
M5`D#*<N(Z1,1^K%S)XIU',;3C[:.0F)J_FEZV(Z0QS+W2%860"*-E7J*+ALY
M<II,WR[-$RJ;98Y'"B>QBD$IBB)G:VXZFUF]4]%4KM0_M0A13G(D2&(!P)&`
M/&#M]LS-<+8[5,)KS_9E8"LIRE/`RQD<8B'`NZ)E'U",:9RQ_P"H*SG*I8L"
M.R5GAS7[,D^J^0(T%[*R',4:S;V4B,B@BX15Z')(U4A_);@J)0`0E#R:VW[&
MJ+16V52*ANM&NM4@!3:NP>X)T3!.&&L>=E&B;52UFZ&+C2W0*973'32I5-+@
M[7K0-4C+GI/FYQ+0O-/B4?-G[N!.16(SYS\X,9]6);K#&M'O<I1,:"\H#D4O
MI"7I$!C^OSH&#I[6_AJ,?E3<@M7MPT-3[)TZN]T*TZ?2R\W]*6GIC>>W[)[0
M]E>*8]HSEW>L:I^C+TOT<^B.7F[F)Q9XVS=:K>><]XPQ18+>!3UR%NEJCHB3
MDFYW'E"O@9K*BNUC#.@%,'2Q4VW60P=>Y3;6VG:^X;ZRNHL]'45+#>"E(02`
M93E/B98R$ST1=<+[9K4XEFY5+++J_-"U`$C*<N4^)PZ8D2S>-)%HUD(]TV?,
M'S9!XR>LUTG+1XT<I%7;.FKE`QT7#9PB<IR'(82G*("`B`ZT:T+;66W`4N))
M!!$B",""#B"#F(VB5)6D+004$3!&((.1!CDZMBL>?/C7G3)KCUSN?F-KAE>Y
M.<+X_P"/D%:(>C3MJDEZ!3UT5<<N9&<C8-VY-%Q"I$'KDZJR9""!%3[CL(Z[
M5?+31?PBLU92TS7M1ZM*"M*$]ZN9>`25`:E3($@3P$<PM5PJOXBW.FJ'W/`-
M4P4$*4>[3(-3(23(<<>DQMA@N<W#FSSN-*Q7.3&%YVPYC>2D?B^(BK[`OWUV
M>PSI5C(-81%L[4,NLF_0.W(4W2*[@ADTNLY1*'.'MH;HIFJA^HM]4AJE`+I+
M:@&PH3!5,92Q/(8F0B:M;BL+[C+3-93J<J"0V`M)*R#(Z9'''#I.`QCN,S<Q
MN*_'>T5>E9QS]BW%ELN0%/6Z_<[;%PTG(('7*U(],V<+`=C'*.3=!7+GLMS&
M*8`.(E-MY6O:VXKW3N5=HHJBHIFS)2D(*@#*<I\3+@)GHCUK[[9K8\BGN%2R
MR^OS4K4`3TR.0Z3(1(;WE'>[O?'O!E[H\E[R]Z>:0]W>[NQYKWAY[N>6\EY;
M[YW>KM]OY6^WCK2=VYWG=:3WLY:9&<YRE+.<\)9SC9ZT:.\F.[E.<\)9SGE*
M7&.;JR+H:0AI"&D(:0C!/(%.2^AK)TR[OEF$XS<R/;WV(AVETD5E=O8DFY4(
M`B/@`F#7PC_^@U/N;^#5%=K&7?9M!?:=ZLT3[+6AUMMQ<O[-+RT`DX)*DD\X
MZ5[KETGM]QBIEWSM,M+<^*I@D#I*0>N1BU:5D9<[!JS>B0_82*D54WSNDH#X
M&$1#?I_S!KF/N6_\B:NIL%):+V4K[EI*$N'/2!Q)/#Y.J-SN#:;0JEOT\P5*
M)($2/B5CN(YJN<HE[R?<*`@)1[9Q$4Q$!W$.H@@/\PZ_1G:54]7;=I:UY)27
M6]:01(Z%$E&'":9$=!$<GKFTM52VDF>DR\HS^..QU(XQ(:0AI"&D(:0AI"/'
M)C'_`*C_`.)?_P#JR_\`_P`7?=?3M;_T78G_`##7RMQPVD_ZMNS_`-%?R+B(
M%WK4=<_2.]%VH2ZCU&*M?+B?K4FM&NE&,DE'3U[E8I^>.?HB5=B^!HZ/VEDQ
M`Z1]C%$!`!U):1]=+[Q=TU*`"MNVMK`(F)I;2H3'$3&(XC"-#4M)?V9M]A<P
MA=:I)E@9*609'@9'`\(WS\\?3XX(8=PKQGELC7V'X[<*.'^6)G*U@P>O%R]U
MB,WVBUK-5?H:=27LCNS2,O8UV[E--HU3>+*^<6$I")]P0Y!L_>>[KI=:]JA9
M56[IN=.EI-1-+9IT(GV\$A(2F:229`:4YF4=(W'MK;E#04CE6XFFL%"Z7"S(
MK#JE$=G%142J1$A.>I640^]#+'^*N3.'?5=PNYJ4I7^/F5L^2<=7\:RC56)?
MTBG7FOSY(V/+#*KN0K]@@H]JQ$$P.<[9RS3`3&%,!U)O>U77"PW/;MV0XE=X
MIZ2:G`9A:VU(U&>&I*B5=84<IQHO=[2T=VH;U;U(*+:]4D!LX%"5I5(2^JH`
M)ZB!RC*_H\9DR7PZY#Y5]'+DP_6>2^.%YN[\5KJ\%0C6YXU<'<3CN$BSK@`J
M,G$6H:88)A\IJH61:&_X=,H:WWF6N@W/9*?WFV$`-/!**M`S0YYH49<4GU:C
MQ'=J^L8S-C5]78KH]L6[$EQLJ73K.2T9D#H([:>7;3P$:?<FD)^Y)Z_(=!=C
M<Z\9B8.D/$?KAM/B/AXCKIM`3^9]G_X,]_L41"*O_H6YO\1;_P!JJ)PY[P!C
M'D[ZH/I,89S'#.+'C:S>G53W-IK3:4D85.R,H*N7260@9-_#NF,F$(^>-D_-
M(HK)BND44Q'I,.HG:+Q76'86X[K;%ANO:O;FA1`5I*EMI*@""-0!,B09'&)#
M<[;2W;=]EH*Y)72+MB=29D:@E*U2)$C(D"8GCE&+/4F?<7,6^K"G0>1./YBZ
M8!QOZ?T?C/#V.X:M62_IU&R.J[/,**>-A(QXI+)I1S@!,+XYCB@J5-94W64J
MA=AL47^X^[PUEF=2W>JB\EUYPJ2WK3J279DC3VAAI&8F`)81A;L59Z+>0IKF
MV5VMFV!MM`2I>E6E0;D!CAS.1D3CC&Y'^'C4LQ?3%QC&V@DV@X@\A9<B(MC/
M-GS1U&PB-U?N&+%NVD$D5TF"1W2@I`!>@.H>GPUR_P!]09_/KZV=,EL,J)$L
M3H`F2,S(")U[L"[^464NSFEUP"<\!J.`GPQB>WJ)?]!W,'_MRR[_`,E2^H=L
MK_NZV?\`/,_STQ)]R_\`;U=_RKO\PQH0XZS4M7_X7F[24(_=1DA]3F7X\KQF
ML=!P1K,Y:EX>22(JF)3D*ZC7ZJ1MA\2'$/AUV&\M-O>_YE#H"D>*9,CS2RE0
M^`@&.;6Q:V_=`M2"0KP[HPY%Q0/Q$B->/IRV'!K_`)[^DHKQEQ];*7.5S#-Q
MI/*"Q)T>S5^'N.0'U8M;IT\=3SH%HJTL7"/R0>)G!`>A$@>*9"DFV]6+NG9^
MY/;CJ'6%U*'*5.M*BAH+0`-(Q00>!QQ)XF<4VP];SN6R>RFU-O)84BH.A20I
M92N9F<%"7$89<A&4,">G6;U(:=ZJ9Z^M2HSE#%>H"\-1,V9%<V,[RLP<+-R\
MC(Q"$A!M92100>(&$A2$;F`1(EN(=E(28-YWJG8U3M[OP\JPJL_;8:T]I12D
M),E$#`]/$\S/,MNUSNNGO/=%L7@7(Z'7-792%$D`B9$QT<N0C.7(W`E/R;ZP
M=FQIR$@H;+!Z7Z7ZTS*^]S2"\5)Y%I.+7J"5M`G=9.':R4R"KML+@NY%3$5Z
M05(42ZBQ7>IH?=HBOLRUT_>W_2)2!#3CHFCB`"F23+A,3D8V=VMS%7OE5)<T
MI>T6<DSG(K0V9*X<<1/CCG$`)QDVL'H8>G9#3*8OXV2]0R<A7K9154O>BY*Q
M7QH]:`JD<BR)5V[M0HF3,4Y>L1*(#XZF+"BU[VKRXW@H69!'6`W+Y(C3B0Y[
MO+6A>*3<U`]1*YQ.K%]-J_&WF1Z\]+P7#-<9U.B\+IAQ3J_6A5:QM<7"MMW!
M58M$ZBAD%".GBRI3"83%46.("&^HE<*JHO>V=GU=V67ZE^Z)[Q2L2KMD8^0`
M=0B14-.S;+]N2GMZ0RPU0'0E.`3V9X>4D^6(I\:L78^Q&K_#O9>QQ5H^IY+S
M'F#*##*5QBS.DY>],T;['03=M8%1<&3=I-X:6<-2`!2@""G0.X`&TBOU?67$
M;UME:XIR@I:9HM(,I-DM%9*>M20KK$XTMIHZ:B&UZ^E0$5C[[@<4,U@+"1/J
M22.HRB1SZ=F*VA_$^R\!)/(B41L:[9&08+G;.TD).9M48_3263$IR`ZCWBJ1
M]A\2'$/AUHT--O#8+;H"D:9R/-*&U#X"`8VREK;.[E()"IRF.DK!^$&46GQ:
MQ1CS!G-#T%;/B*LM*%.YPXUVR3RU(02SI%6_2#ZOV4[QW804743=K.17Z3;`
M4O0FD7;9),"Y&X[A673:V\&+@LNLTE>E+(5+U:0I$@GE+/K)/$QBV6DIJ"_;
M;>HT!MRHI%%PI^N2%3*N<_HY"(Q\B\4X]N>#?4ISA::A%SV7(SUC:ICJ.R$_
M375LK.CS-@!E*U1M(`L4Z$,];/#$42*``(='PIIB606:X5E->+':*=Q2+:K;
M2G"V/-+B4ITKEZ0Y]?,QJ[I1TK]NNUP=0E5<F^)0%GS@@J,TSY'B/H$;AB4R
MHXM_B"\(4O'5:A:94*5Z>LO&U.M5]@A'PU?CF<->W#9C&,D2@DW;)+',8"A[
M3&$1W$1'7,C55-P]S=;5USBG:IV])*UJ,U*)6W,D\XG!IV*/WFTE/2H2VPW;
M%!*4B02`%X`1YM*_=,)S/&Z-3B:1=Y3G@'J&M<G.\P15-MDFN7%IY551TT5O
M[%1Q&I/PM"B+H67;!P"GWX1#Q$>Y.TMV1?5%3C8VE[&[H,E:1ZZ6?=G&7=S3
MJREA*.5(J+>JU`)0L[B]J=YW@2H^JGEKRGKQEGQC>5SKPYQ_6]8S)->]0*(?
M,\&<UN.53QQQSS8\$$HS%.0H].`B3*1<LY*XB8&:C)5@Y0*NX342;'E4E5R`
M@Y.<.3;1N=X_AE3O[-4E5WM5:MRI8&)>;)4J12)*4%)*3($%6@@'4D".A[BH
M;9^>GFMRI(MUPI4H8=X-K&E,P<0""")F8&H$B2B8]3''O"]>XZ81QA@NI35D
ML-8Q73XFF0,S;I).6L;Z*AT>PR4E)!)!JBX630V(7H3(0J92E*```:^?+W=7
M[Y=JB[U*$(J*ATK4E`(2%*SD"2<\<2<8[!:Z!JU6]FW,*6IEEL(25&:B!E,X
M?)&8]:N,^/+!CW_]L/5U_P"Q^9_Y;H&OH>I_^K-M?XLC_:/1QNG_`._KY_AZ
MOYC<:3\5XHQQ3N)_H\YOK51BXG+.0^?-H@+I>VPNO?L_!UK(=6:P,0Z6.X,D
ME&Q2)/O"*)$R)G,<X?+44,;J-RN%;4;BW):7G%*MS-F2I#9\U*EMKUJ'2KB3
MGAR$0.AHJ1JRV.XMMI%:[<RE:^*@E:=(/0.`'SF-H-CXAQ'J%>IEZT&++3'5
M.=R3%8>HE9P1;,@C*KQ.+["=O!,(F89&C$GCY@FS29E*(H(*&Z#J%`H@JH!H
M$SN1S9>P]KW!@N(H%5"U5"&Y:G4S62DSD#,F>)&(!X")>]8V]R[NOM&\$*J@
MP@,J7,AM4D@$2Q$N@<^9C?[2^)F7(/TO7G"BP7^N2V8U^(]^X^-\AI.)X:JE
M9;#CZQTJLS(NEF!+'[EA0DV@'.#;S0(H")2";8!XW5[DMKWO!&ZV&7$VL7)N
MI+?9UZ4N(6L2GIU*D>,IG$QTBGLE<WL\[?==0JO-$MG7VM.I2%(2<M4A,<)R
M$3O^E<#^?IZB'A7_`$3$F[Q'./GTK@?S]+5/"O\`HF'>(YQ42LT.X5(@@Z[Z
MR@[)I)$,HH<?[)2[B.P>WXM#3O)&I0DGIAWB3@([=P[;-$N\[72;)`&XG74(
MF`#MOT[F-L)OL!OKR2A2SI0"3T1<2!B<(K$.50A3EWZ3E`Q=P$HB`AN`["`"
M&X:M(D916*;AN@Z05;.44G#==,Z2Z"Q"JI+)*`)3IJ)G`2'(<H["`AL(:Q*^
M@H;K1.VVYLM5%N?;4VXTXD+;<0H24A:%`I4E0)!!!!&<>C3KC#B7F5%#J2""
M#(@C(@C$$18S'&%'C7GG6<&DF<#]PJ)EW2K0A]P,`D:*K'0`"B'@'3L'P!KA
MMB_\8?<?MN["\6BQLMO)<UI;+KRV$*G,%+"W%-``XA.G2.`$2.IWCN.K8\._
M4J*92)TI"B.E0`/EG.+_```````-@#P``]@!\0:[X`$@)2)`1&,\3G%%1P@B
M9,JRR:1EC"1(%#E)W#@&_03J$`,?;QV#QVU<$J.0)E%)@10>R#:/3[SL3IH!
M\Y;H$R9/B[A@WZ`'XQV#5R$*<,D8JY0)"1,Y1U7TK@?S]/\`E_EUZ^%?]$Q;
MWB.</I7`_GZ>GA7_`$3#O$<XYK":C9-4Z+)R1=1,G<.4OM`G4!>K^;J'5BV7
M&Q-8($5"DJP$=KKRBZ/#UR*S6TX%<QO6BHF;<?9*,^YQ8YEF''V6KE:5D8*S
M*V]A*)1CE61.HDE[N2-93$<*M_,*(.&*J!DP4,3?ZRLEJ5N[;.UJRU/,%%I>
M2:@*5)2=!&H2Q[79P!D"%!0,H^?+I<4[<OM_I[@T[JN#1#)"9A6H&1GR[6)$
MY$$2G'=Y=PWD;#?IQ>AU1L@5.>K]O;<M8&S2]<>1+\LO`,;5<OI#%)SK$&XK
MQ3H8F104536`AD1/T'V,4P!Y6VY4=SWKNZJHW$+I_9I0%`B2BA&E6D\1J!`(
MSE,81=74-50[7V[3U*%)?%:%%)!F`I>H3'#`@XY<8V(>O):S8YY&>EKE')]7
MLUQXPXYY`R5JR1`UZ`4LX/+-%.*N]A$UX%,ADY>1-%MW)F;182@ZZ%DB")C"
M`PGW04QKK'N"WV]QMN_/T:4-J4K3)*@L$ZLPD$C41E-).0B5>\9\4ETLU95H
M6NTM5)4L)3JFH:2,,B93T@YR($:]^,$SR3NW$7UOLA\64,NXOS5*<IX7+M8@
MHZ-?UK+K.KK3\Y8+/"(QW8*X)84:LJZ\RV0ZSBJD=$G4H)0&;7YNQTNY-J45
M_P##5%K%O6RI2B%LE>A*$*GEIURD3S!.$1>TN75^R;AJK/W[->:Q+J0`4NA.
MHJ4)9ZM,Y@<I1^L><M1]1SGSZ/\`(8:Q_E9YE[C178!IRFR#9XI9LN5C"$CB
MW563G@,(/X5PG'R+DSAUV#N5YGRQ$Q5$^U*[;GY)V?N9%T=ITVRO<6JD;0<`
M53[L!,A)4R@23.0;G.4H4MZ_-.Y;&J@;>-?2(2*A:AP$M9)XC!1F93*Y2G.(
M;<ALDN<?8T];/B[.8QRVXR-DGEK4\BL'L11I21J58IE?RE,2"DY<YU(@$A6T
MPG,LBQG214)`SL@ICT@<0DUEH165FU;\T]3BB8MBVB"X`M:ULI`2VGZQ3I5K
MQ&G29\(T=SJC34NX+0MI\U;U:E8D@E*4I<.*SPG,:?2F)<8W-$9OO_,9Z03C
MR$AY9#TX(I)PY\B[\JW6^A5Y#LN7/9[#=<#"`=!S%-N(!MXAKF)4G^&6YA,3
M-[5Q$SZUK+G$\DK\]6-4CI]ECA^@Y%M^H;F!QP']89#F/DNH7Q7%^0N%UCQK
MC:XTRKC:$2Y69L95JPAG8'V9,W+>23;'4(J;J!NX*J)#I`?;UV3;1N_W9';-
M"XSX]FZ(==0M6GU4TDJYD$3`(X@B8,>&Z*X[;WR+[5H<\(Y0*;;4E.H=Y(@`
M\!(RG/@09$1N&](Z_<ILK<&<79-Y@OY21R]?)&VV5%Q.5Z,JLP-$?3SHM',_
M@HIA%H,3N(1(BR0'036.@JF<X;FUS+WDT>W[=NVHH-M)2FVLI0DA*BL=X$C7
M)1*IR5@<2`01$ZV357BMVZS67PDUSA4K%(2=$^Q-(`E,8C"<B#&9O4.345X(
M\OTD4E5E5..F6R)HH)G665.:ERX%3222*=150XCL!2@(B/@&M5LN0W=;)Y>.
M9_GIC8[EQV]6RS\*[_,,:/.(>*KYEO\`AIY_&%%KDI,7RPXES&6!JY&;A&8E
MGT3E&=GO=;)BLFFY6D7[:,.1ND!>I94Q2E`1,&NL;CN%);??JBOK%I12(J6-
M2Y]E(4RE,R>`!.)X#..>V6CJ:SW3JI*=!54JIW9)EB2'%&0',RPYQB#TRN=N
M=\UYR]./B=QS)D:N8;P-Q[FX7FQ`V?&T?'0:-GK#2891!0L<E'*RK$HODVB*
M':7:G6<+]L4A,FKMM=^;0L]KM-\W'?`RNYUE:%4*DNDJTK*2>R#I.&HG!0`$
MYXB-=M'<=RK[A:K):N]30TU,15A38EJ2"!VB)C'2!B"292P,0K>\G^0W!9]Z
MBW$7%<%F6@\W<^\YF%TP<\JE%;6&-G:)8IJ1$7\>_D&,HQ>)3L4ND+<4FRQ3
ME7WZT^RKTRM%BLN[4V3<EP-*_M6DM*D/A;FG2X$C`@$$:2#.9$I9&8C0+NUS
MVZ;K8Z,/M;@J;B%-%")ZD%1Q$P?.$I8&<\Q(QL&N47=VOK,7-.[IR$C;6OI,
MSD?<)@C-59H^N*6)UTI\Q7S1L2/5<.I<JI@*GMU";Y)0#8-0NC72J]US1I)"
ME.Y$E`GB$=\-.!,\$RSB3U*'T[\6*B9>%D4%&6:N[,\<L3.-9"D;*_\`A)].
M%O[HF/,I^HZ^55:^Z)+S:*/TJN?WY9KY7S"*'C\\Q0+X^W4]2I/\5[T=29>Q
M$\1+)'&<1(I7_#^UC2J?M0\#/-<;-*WCBVY/]23UX:!5(A\ZL-^XCN:Q5$E&
M3M-O,3DI7XUE'1[)T9$J#E=T]4*D4"&-L<WC\.H%45M/0;&V=6U*@&&;B%+,
MQV4A:B21P`&,2VGIGJK=>Y*=E)+KE'I2)9DH``'6<(UY<,KXXY'9-]$[BQ1,
M=Y0:92X-Y.RI8^1J=BIKZ(A*;&!<VUC.L:0<"4X>590IDG`.$VQDWBI&X`=0
M=37=%&+)0;JW!6/,>`NK#2:;2L%2SW91*7&95,:29I!5@(B]@J3=:K;]FIFW
M?&6]YQ3\TD!(UZL^H8SECAG$OZYBB_9<G_XE_'=$K<I,6ZWVET6K1)&+I):P
MNHV1M\R9C#"JDF21>.V[`Q$")"<5%3D*&XF#>-/U]);J?8E95K2BF;0-2B1)
M(*&TS5R`)Q)R$XWS=)45CV[*>G0I3RSV1(]J169#F3+"7&,,<#,FAR]YL^D'
M5\44+([=;@KQZME<Y#REKJ[N$AJQ+-(J>CC(MWZP="J;EZLW20[P(*J+.`2!
M,3)J"&SWC0G;FU-RU%Q=9E=JY"Z<)4"I8)2<N8`),I@`3G(B-;MJJ%ZW!8V:
M)MV=NI5)>*DD!)`4,_*`)R,S*6!C&#VX>G+.>H5R,G^8MXY*\6:XTYB*9!?<
M73U:?E,-WN:I2S="!RGDJ3:$D):*>VVPD>R*K-*,!!"-<%3:O%$UC"7/33;V
M9V=1,[9:H+@^;8&Q5E:4O-AP8M-`R20A.E()7,J3-200(Q%/[67N:J<OKE71
MLBOU^'TJ+2RC)Q9$R"I4U2"9!)DE1!,;99>4B<@?Q#V&[?2WR-@I5RX`OY&L
M6Z'(J]K$K%3\%=%H=^QF&R1X]9J\;.2'3Z3[B4P;!KG+33M#[E:NFJTE%4U>
M$I6A6"DJ2M`4"DXS!&,35U:*KWH4K].0JG<MA*5#%)"DKD0<L1E&I#C5RKY.
M<3<4NO3BX_UW*N/^=LSZADB[GFH8TCYNONL02PECY=09&>8/6I6TBJ@BZ\T5
M$J18]'S!7`)&UTF^;=L.X[B-[7E5.]M%%D`2>]*2'DG4#))&0)3*<]1TZ9Q"
M;5>KO9*,[7MB7F]QJNAF.[!'='`^<#F9&<I:1.<HGSZV7,^"F7_)G@IRGXNS
MJS(E$JERX.9=J$#-V2;N&67A(X@2A'B:*4?!,V:[MTP=I,A=*J$*HW53ZU4M
M0[W5[6<:;M^[=O5XU*=6BO96I*4H:$^S*<U'!*DE6D"84#@8DF_K\VXNLVY>
M:,Z0VE=(XD%14X98Y2`S2H"?$$8B-A6$N=UEXC4#TJ.(_)?'&2+#GGE%CFD4
MY]9CNXE-&DSC8\)!((7OW@X+(+2K9C*-N^DEUN`.BH!_E@.H5=MHTVY*W<6Y
M+'4,(M-O?6L(D3W@.I1+<L`DD&1RD1+")/;MQ/62ELMDNS+JKC6-(253'8(D
M`%SQG(B<L9@QO%UR6.AQY:,>LWP>M7ZN+@6$@#9;A%,IH.A8/`:N%?HY00!)
MLY%'L.%1$HATD,8PB`^'@.OH>I*?X6;:$Q/VLC"8G_6/<(XW3A7Y]OAD9>SU
M<#Z#<:E:C&2O_C^]$M(8B8!5#U#,AJN$1B9(%FR(Y+K(E6=(BU!1L@8/$#J`
M4HA\.NB5:D?G+=)U)E[#:XC_`%:^G&(?2I6-LV`:53]J+X'TT]&$2]Y9\@[W
MZ<OJ">JI9%XK)]6R1RVPM31XC7NETP]ECY&Y;0Q6SE-TX;.HW_VE]WT5RBDY
M,FN@*9DNI1+JC6W+-2;VV;MYE)8=H;=5+\8VM>DA`U3!`D<04D8@$&<\#&ZO
MET?VON>\.J#S=56TZ/#+2G5-79QG(C`@C(XB4L1&QG.GJ+<C^)O!/BEB[)-`
MS#D'G/RZX[7B"J]TK$-!)S%"SK*5E%I1Y2U5U2.*T-,,+'<(P19IMND5FITS
M)B([:A5IV38MQ[QN-QH7J5C:=MKFU*;45:7&`J;B4JU>:4H4-1.1G.)1<=SW
M>R[;HJ.J:?=W%74JTI6D#4AXI[!4F684I.$LQ*424/G10#FV>&VZA]JOV?\`
M2UJ19DR\WXHE?BY<8N2#RE[Q*#Z8LS&LP*9C%6E'ZBCITY$FW6WA(1J8TA,/
M/';Y)2-R#^$5+KP>MO=]AIM3CWH@2`Z5*."1\)Y`QZ(J-6*EZ4<_H&9^3IB\
M5>6$%6VQX['D4=`QB@1U:[2=!Y.OA`-A418(&%E&HB/B5,3*`'PEW\=88VP]
M4J#EP5/DA$PD>4XGKPCT]HMMC2R/*<S\PC/&&%IBV12N8LGS!F55:)'?0JDZ
MZ*U:N441^7.NN^*3=M$)&#9L4`*58WR]ND"=6EN_=4SGLFVHG4DR5I$R/T1Q
M*N?++G&72ZG$^)J#ZOA/Y>KE&6,:YD99=L,^:F(&/1JKTLG-D=I'2//S;DO<
M3;1:"G29O'LVH=U110.XIUI[%*41WU5PM*[4PCQ9_OCN(0/JI'$GB2<)#`8Y
MQDL50J5GNOZI/'F>CHC),-=*W/0)[1'2:!Z\5T^:IRZARIL7/N]^K&+.6RYC
M=*K0[U$Q$U`\%-@$NX"&^O>I*AA_PSB3W\@=/$3$Y'IEB1PCW0ZA:.\2>Q//
MXH[]R]:,S-2.G"+<SYR5DT*J<""Y=G256(W1WVZUC)(',!0\1`HZ\$H4N92"
M9"9Z!S^.+R0,^,=:$_%JSKNK$>II3[>(0F@9*``*GC'3A=DG(-R&$/,MT7B`
MIJ"'S#B4#;=1=_3N'0P*DB;!64SZ0`9'D9&8_P`T6ZTZRW/MRGY.<86A,JU&
M_3%DQ!<C(US($2Z7CW$0JOV"RO9`%F4Y5'BNQE^\W,1P1(?OZ93>('(`F'</
M6VJH6F[K23<H5`$*]'FE8Z\)Y'H,8J:AIY2J9SLO#"7/I'RQ&>XYJR5@>V+U
M&R+IR[`4Q<Q?OE(SB-G84QQ3(Y8N!,5P@<GX-=(#F!%7<!`0$HC(J2T6Z]TP
MJF`4+R5IP*5<B,CT&6(C!=JGJ-SNW#,=.1'1_EA%L/,WX]N)17AY8V.;(<-S
MQ,XN=S3));IW$&4XW(96`65/OL#A$&P;AN8H;FUDHL]=2'2ZGQ%/Z21)P=:3
M@KR&<>9JV'?,5H7R/FGR\/DC',CF*4B'1V4BH9LX(!3=/F$ET54S^)%VSINJ
MLU>-E0\2*I'.0P>P=;!NUM.IUMXIZOE&8/08\%5)29*)!B07%O*)[9D9]#F<
M"J!JR^=`7KZ@W0>,?$0W^#N:TNX[<FFMO?`2(<2/AG&705'>5&F<^R8V$:@$
M;N.KD(.%EEF;B5AXN37CU>\P7D(]H\68K>'WUFHY14.V5\/G$$HZ]6WGF@4M
M+4D*$C(D3'3+.+%MMN$%:4DC*8!EU1S%VC5UV_--F[GLG!1+OHIK=I0/8HGW
M"FZ#AM[0V'5B5*3YI(GRBX@',`Q^7;)D_(1)\T:O$TUDW":;MNDX(FX1'J27
M(18ARD62,.Y3!\HH^P=$K6@S02"1+`RP/#JBBDI5@H`B<\8_2+1JW4650;-T
M57)^XX41133474W$>M8Y"E,J?<1\3"(^.A4I0`420,NB*@`8@"9C@1U?@8==
MVYB(2(BG+\_<?.(Z-9,5WJFXFZW:K9%)1R?<=]SB8=]7N/OO)"75K4E.0))`
MZIY1:AIM!*D)2"<Y`"?7')-&1ISNU3Q[$ZC\$2OE#-$#'>E;!LW*[.*8F<@W
M#P(!^KH^#;5H<<``"E23.6)PGG+E/C%=")DR$SGAG+*<5?),^\DX\HV[[=/L
MH+]A+O(I;"':25Z.M-/8?F@(!JFM<BF9TGIBNE,YR$Q%-]&QTHD1"3CV4BBF
MJ59-%\U0=I$6)OT*D3<)J$*J3?P,`;AJJ''&CJ;4I)E+`D?)%%(0L26`1TB<
M<P`````````````V``#P```/```-61='Y4335(=)4A%$U"B4Z:A2G(<HAL)3
MD,`E,40]H#JH)!F,X$`X'*/P@W0:I%0;((MT2;]"*"9$4B[B)AZ4TRE(7<1W
M'8/;H5%1FHDF*``"0P$4&D9&L%'*K&/9,E7J@+/%6C1!LH[5#JV5<G13(9=0
M.L?E'$1\1^/5RG'%@!:E$`83),NKE%$H0DDI`!.<AGUQ^58N,7?(2:T<P6DF
MQ!3;2"K-NH^;ICU;IH.SIBND0>L=P*8`\1^/0..!!;"E!LYB9D>L90*$%060
M-8XRQ^&*QF3,RYG)FC8SDR8HF<&02%<R(AL*1E1+W!3$/#IWVU36L#2"=/*<
M5TIG.0G%+W7&=E-O[N8^714[R*'E&_926W$>ZFEV^A-3<?G``#JO>.3U:E:C
MTF*:$2E(2ZHK$:-4UU'*;9NFY6`"K."(ID75*`[@514I044`!^`1'5"I1&DD
MZ1PBND`S`$XH-XJ+:.G+YI&L&KUZ/4\>-V;=%T['?JW<N$TRJKCU>/RQ'QU5
M3CBDA"E**!D"3(=0X10(0E14D`*.9EB>N*Z31J@HLL@V;HJN#=;A5)%--1<_
M]=8Y"@94WC[3"(ZH5*(`))`RBH`!F`)F.,WBHYB+Q6.8L8YR_,91TY9LFR"K
MA<0-TKN3))D%RH4QQ'<XB/B/QZN+KBY!Q2E)3D"3@.0Y1:$(3,H`!.<AQZ><
M>11UPP]7.H53EOQ<D.+?''DFCRIR/<IY_P`T<F72"?6IG%VM)"'82[U.:<#9
M$C5"$;$4A6@-"F@W!C@V*H4":^E!NGW;5=5;K^BXUM`+>PA(H6FU!$T35I[(
MTG4HR69^L`&HC&.)&P[WIV:VSJHZ6K\8ZHFJ<6"J2L`3J[79`FD2[!RGA'I8
MX8<<"<4^+F!>/[R9;6Z9Q#C>#IDA;2M!1&4?M$U'$FJQ%P!GB46$@[5*V(<0
M,#<I.HI1W`.$;JOOYBW!67E"2TS4OJ6$3R&29RPU2`*I<9QUBP6KV-9Z:V*4
M%N,-!)5+,\9<93)ET1)7W7&>?]Z^[F'O04@1&2\FW\^*(`)02\YV_,=H"CMT
M]6VVM#WCFCNM2N[G.4S+X,HVVA&K7(:^<L?ACZZC(U\JU7?1[%XNQ4[S%9TT
M0<*LUA$HBJU463.=NIN0/E$$!\`^+1+CB`0A2@#G(D3Z^<%(0H@J`)&4QEU1
M%?-G%IMG#D+Q7S'8[.DE5>+\[?;W&8_]R)NPM>1K-62U6JV-_,JO"`P1H;-T
M]<M4B-U#J.W`&ZR@0-Y':=Q>R+'<;6RV357!#;9<U2T-(7K6D)EB7"$@F8D`
M1(SC37"S^T+I15[JQW%&I:PB4]3BDZ4JU3P"`5$"1F2.42VU&8W<<8&3,JRK
MD&C8'"Y.TNN""0++)^'WM54"=:A/#V"(AJ[6N03,Z1PG%-*9SD)Q1]U1@)H)
M!&L.TV4%5LEY-OVVZHCU"H@3M]*2@B&^Y0`=]5[QR9.I4SGB<8IH1E(2'1'U
MW&1K]1JL^CV+U5BH*S)5VT0<J,UA$HBJU.LF<S=01(7Y1!`?`/BT0XXV"$*4
M`H8R)$^OG!2$*(*@"1E,9=455F;1PHBLX:MEU6QP.W5602540.`@8#HG.4QD
MC@8H#N40'<-4"E)!"20#GTQ4@$S($Q'D(6RZ(*J@#HH`"AP#Y1O@,/V=?48M
MN&4<V-29YQ2^MT=]_-%WVVWZC;[>([>WV`(^S3V;T13Q!YQ(3#]CHS9F&6\X
M2JK'%T0]50@*LR,![/F.S1XE.I6JVQ%5(Y:U&*B7WO)J&3:);@W!3N&.!-'=
M6JU2O9EG2#<5CM+/F,(/UU'TS]1&*CYTI#',IEM2\15F5.#@.*R.`Z!]8Y<(
M9?YI9#Y!S\9!MT$XBNJ2,?#TC%]<.<8]-TY<(QT(W<]HB)IJ745533*<Q"HI
M";9%,@>U:MJ4-C94\HZJC25./*SD!-1'HIS/,\28K4W1^M6$C!$Y)2/@'6?\
M@(EYR2Y!Q7$_#E=XKT>8;KY.>P!9?,=BCER]<&K.H`^DX])=(PB6:G1/VD_$
M#-HM,AO`RJ8A%K#9'-S79>Y*Q)%N"]+"3];29`R]%.9YK)Y&-E75J;=2IM[)
M_O!$UD<)YCK/Q"+RY0YI+Q^XA<;\<M'9&MENL12YN10(8"+-Z]7$HBV3AE";
M=12N9MVV0W\.L.X'QZQ=NVDWO=-?7K$Z=I;B1^LK4A/P)!/P1ZW"J\';6&)^
ML6$D]0D3\<HS;ZA.<7>,<286NM?=%))OLHU2SQ/2<`([2A8&3L!D1`!^6@[3
M,5(X>("100'VZU&Q[0FX7.KI'QZH4RT*Z-2@GX1GY(RKU5FGIFG4><7`1Y`3
M&,^9V>7=7KO%CEMBQ^F9K+"\9D,<XF82$79(=I/!7)<4]NI!R$8[;+%^<DJ3
MJ+L<@"&PVI9DU#]RVQ<4]I,CT@I44ZT](FDCF,\(\+I6%MNGN-.<#/R@B<C\
M!C#_`"_NU=RSBC'',O$CA9./.Y94S([5NL*<O4+`BH`PJDFHT.15I(PTJJ9D
M*X"7N).&JA!Z#%'6UVM2OVNY5&U+F`5R+C1/FK3]:4\PI/:ES"@<8Q;DZBII
MT72F/9\U7,'A/I!PGTB,85CFC3LYTI+#?).81AI=N/5CG/!40.I6YSM@BU2O
MC=`@'4AWH@5%V\2#H42'J7*4Y0<%V%1M2JLU8;M8$ZFC_6T\_/3Q[L^D,TI.
M1R,NS'@W=&JMKPM>9*^JYR/Z71S/P\XB-=[19L=6F6IUN23CYN(53!0$7)7D
M?(L7217,9-PDB@8S:6@)IDH1PS=I&,FNB<!`=]P"44;-/7TR:JF.IE0Y2((P
M*5`XI4DX*!Q!C6NN.,N%IS!8^`C@0>((Q!BU0R\8"E*#L.DN_27K-TDW'<>D
MN_27J'Q';VCK)]F\98QY^)C8%Z:60!L?)!Q&"N"F^.[(XZ0$1_`OH8-Q\?[>
MH9OZC[C;JG)?V[?]*-Q8WM=>$GT%?-'H"UPV)G#2$-(0TA#2$-(0TA#2$-(0
MTA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1_/A7
MR4?OK?E!?PJG^\_M#K[7%'AY(XH:G&*/UE''P\P3^\T\'#Q4<Q]EN1DE&RDA
M)JO#LF+>,9=]P)R,8UH`^6CV27@DT9(B81!-,I2]1C&$!,8PC:B@0V"$``$D
MGI)S)YGIBIJRK%1)($O)RB3G&W-,)AH)_DK8TF,S,44RU:P74WP@HWLN:)9@
M8Q+-((_.-5<2P+@9)ZH785)!TQ;D,"B@B307ZV/74(L+)*6GNU4+&:6`?,'Z
M;RAI3R2%J.`QV%!6MTNJO<D5(P;2>+A&?4@8GI($86@K]9\QY7K\;+S#NQ6_
M*^1X"+E)5\N*\A,3=SLK%@\>.#"(`*BIWQA`H;$(0`*4`*4`#:O4K%KMRUM)
M"*6F840D9)2A!(`^",1%0Y55*4J)4ZXX`2>)49?/$J?4EY,M<G\J\APT`]3/
M2\2))X7J2:2Y3M@2IPKM+(Z:F(/0=-U:5'1`,&X&30)XB`!J.;$L2K=MQAUX
M2JJD]^OGVY%(/4B7PF-C?;BFHN+B$'U37JT_R<_M3^")->HUGQ"R<5_3F6;N
MRF<6;%#ZW/Q[OB=Q&56D5A0Y@WWW+(*.@W^,!UH-C6=5/N*^@CLHJ0@=16XO
MY)1GWRN"[=0D9J;U?`$CY9QB;&.=1R_Z</(C#4B]!Q:.-%CJ&=*4@8XJ.%L>
M2EH1B;4BV#QZ6M;D9MX=3;8")R"8>S;6SK[3[,WU0W5`E3U[:Z=P\.\"-2)]
M*@E('ZIC'IZX5-B?IB?64ZDN)_5)DKX"3\,1WXQ<O8O%DQ:Z%DH[J7X_9LAE
M*5E^#:B9RYB6CU(S6)R57VGB`V6BNE".RE*'4Y;)&3#90J)B;O<&VW+BTU64
M,DWJD7WC*CA,C$M*/H.#L]!,\ISP;?=44ZE,U$S1.C2L<AP6.E.?2/)&#+_*
M2N.;I9:++RC"4=5R349)34:Y*YB;'$K)IO(&T0[D@BF[A;1!N6[]JH7P.@X+
M[!`0#<4:45U*W5M)*4N)GI."DG)2%#@I"@4D<Q&&^X6'5,J()2<QD1P(Z")$
M=<=4]S5-R43#0DC+&?Q]<3<-Z^1VH"Z\,P=*BX7B6#L^[A&%,[,98C3J%!%8
MYSIE()S]7HBV--N+=0F3CDBJ7UB.)&6J6&K,B0,Y"+36J4@()FE.70.75QE'
M3?64?\X)_>:]/!Q;XJ-KGHSW,TYS+.P%8#@.)+LMT@;J_!/Z\&^W^OKGGO1I
MNZVFI?\`Q+?]*)#M=_O+L$_=J^:/61KYKCI4-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA'\OASD`
MP.%P[H^"RG],G]<=??2:;`81\V*K3J,4/K`-^,'_`&R:N\-T1;XTP^L`WXP?
M[PFGANB*^-,5U<EO%T6;99XNJVCDUTF#<ZX"BS3=+F=.BMTOF)"Y<FZU!`-S
MFVW$=@VM%(A)*@`%*SZ98"?5%37*(`)P&49/P=GQOBS+-,R<X`'#C'CN1M\$
MU/T*$<VZ(A)-2F)J%$IB]E*TG:+'$0VZ$AWU@7:U&X6YV@3@EX!"CR0I0U_8
MF/+&117,4U4BI5FW-0_6`.G[4HQ6?([QRHJZ>O%73YTLJZ>NU5BG6=/72AW#
MQTJ<?$ZSARH8YA'Q$QA'6P%*E(TI`"`)`<@,AY!&-XU1Q)F8E;G_`)#(W/!W
M!NM).^ZXQMA#(=<E$P7*<R#Q?-]S.R*H4?P9A@6C3I#^H`:CUFM!I;M=J@CL
MOU;:AU!A`/VIQLZZZAZBHFP<6V5@_B*E\0$8WP+R()C._K/)1=0:?>*9><3Y
M":E.!R.:1D>NNX"16.B7\,I!2:C.41#81!=B00\0#6;>+1X^C"4`>):=;>;/
M);2@H?Z0U(/0HQX4-U\._-?]2M"D*_56)'X#(^2,*IWU1),B1UP.=(A4S'*H
M42G,0`*8Y1V\2F$-P^QK:FG!,Y1A"M/'..<ZR>_?$8D>/5G18Q@C%,!76*H9
MK&-CJJ-6"9S`)_*M17."1!$03*/278H``6IHT()*0!J,STDYGK/'G%QKU*E,
MSD)>3E'$^L`WXP?[PGW-7>&'**>-,/K`-^,'_;)IX;HBGC3&Z;T#[8,QSZ!D
M)]]\(Y$5V$P#OVY"L?`'P_*US#WO,Z-EJ5_Q37]*)?L>I[V_!'W*S_-CVT:^
M4H[-#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA
M#2$-(0TA#2$-(0TA#2$-(1_)Q<>4[Z^_TNW[RF^WT<VWZQWVW\=M?H@G7(?U
M>7Z4?(:^\UF?>Y_HQ1_(OTO_`%;U7M_=_:BWUGWOV8^_D7Z7_JWIV_N_M0]9
M][]F'Y#^F'ZM_P`O9JGK/N_M13UOWOQ0_(?TP_5K3UGW?VH>M^]^*'Y%^E_Z
MMZKV_N_M17UGWOV8_9O+]*7<^FG1T&['<^CW;Z.X;K['5\GM]W??I\.O??QU
M0:IX=U/RP];]]+R13_(OTO\`U;U7M_=_:AZS[W[,??R'],/U;U3UGW?VHIZW
M[WXH?D/Z8?JWIZS[O[4/6_>_%#\B^#Z8?JWJOK/N_M17UOWOQ1\_(OTO_5O3
MM_=_:AZS[W[,;T/X=SR__D5)VOI#U?4-DW?WE[F\KM[PJ?M\C]_[G]7^C\>N
M5>^;5^1UST?[VSE.?U^<3SW;Z_S,-6N7AW,Y2S3RCWB:^0X^@H:0AI"&D(:0
MAI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&
(D(:0AI"/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
